Abstract:Brain imaging studies have consistently demonstrated brain abnormalities in patients with schizophrenia. These changes are largely confined to decreases in gray matter volumes and enlargement of the lateral and third ventricles. To date schizophrenia has been considered to result from abnormalities in neurodevelopment, with brain changes to be static. However, schizophrenia has long been thought to be a progressive or a degenerative, not a developmental, disorder. Indeed, Kraepelin considered the progressive clinical deterioration to be the hallmark of the disorder, naming it dementia praecox to reflect this particular aspect. Lately, others have re-emphasised the importance of the decline in functioning in schizophrenia as a clue to its pathogenesis, suggesting that the brain abnormalities in schizophrenia could be expected to reflect this clinical progression. Indeed, we and others [1,2] have reported brain abnormalities to increase over time in schizophrenia. Interestingly, not all patients show changes in brain volumes over time: we demonstrated that the changes are particularly pronounced in those patients with a poor prognosis in the first years of illness. Moreover progressive changes are most pronounced in the frontal and temporal areas as postulated by Kraepelin over a hundred years ago. Interestingly, white matter did not change over time. Finally, the progression in these frontal brain changes appeared to be attenuated by treatment with atypical, but not by typical antipsychotics. Thus, not only are brain changes progressive in schizophrenia, they are clinically relevant since they are related to outcome and my be reversed by some of the atypical antipsychotics. With the evidence pointing to a link between progressive disease and patient outcomes, questions such as whether these changes can be reversed with early pharmacological intervention and whether there is a point at which the brain changes become irreversible, become pertinent. References 1. van Haren NE, Hulshoff Pol HE, Schnack HG, Cahn W, Mandi RC, Collins DL, Evans AC, Kahn RS: Focal Gray Matter Changes in Schizophrenia across the Course of the Illness: A 5-Year Follow-Up Study. Neuropsychopharmacology 2007, 32:2057-2066. 2. Cahn W, van Haren NE, Hulshoff Pol HE, Schnack HG, Caspers E, Laponder DA, Kahn RS: Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. Br J Psychiatry 2006, 189:381-382. from International Society on Brain and Behaviour: 3rd International Congress on Brain and Behaviour Thessaloniki, Greece. 28 November – 2 December 2007

Antipsychotic Treatment Effects on Progression of Brain Pathomorphology in First Episode Schizophrenia

Neurocognitive and Clinical Predictors of Long-Term Outcome in Adolescents at Ultra-High Risk for Psychosis: a 6-Year Follow-Up.

Short-term Effects of Antipsychotic Treatment on Cerebral Function in Drug-Naive First-Episode Schizophrenia Revealed by “resting State” Functional Magnetic Resonance Imaging

Predictors of Antipsychotic Treatment Response in Patients with First Episode Schizophrenia, Schizoaffective, and Schizophreniform Disorders

Treating Early and Treating Well: the Importance of Restoring Global Functioning for the Brains of Schizophrenia Patients

Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study

Progressive Structural Brain Changes During Development of Psychosis.

Neurocognitive profiles in the prodrome to psychosis in NAPLS-1

A 10-Year Longitudinal Study of Brain Cortical Thickness in People with First-Episode Psychosis using Normative Models

Pretreatment and Longitudinal Studies of Neuropsychological Deficits in Antipsychotic-Naïve Patients with Schizophrenia.

Brain functional connectivity data enhance prediction of clinical outcome in youth at risk for psychosis.

When to Initiate Antipsychotic Treatment for Psychotic Symptoms: at the Premorbid Phase or First Episode of Psychosis?

Prolonged Untreated Illness Duration From Prodromal Onset Predicts Outcome in First Episode Psychoses

A Selective Review of Cerebral Abnormalities in Patients with First-Episode Schizophrenia Before and after Treatment.

Short-term Medication Effects on Brain Functional Activity and Network Architecture in First-Episode Psychosis: a Longitudinal Fmri Study

Trajectories of Social Function in Patients with First-Episode Schizophrenia: Analysis of Data from a 10-Year Follow-Up Study.

Non-psychotic Outcomes in Young People at Ultra-High Risk of Developing a Psychotic Disorder: A Long-Term Follow-up Study

Trajectories of Cognitive Function in First-Episode Psychosis: Associations to Clinical Outcomes and Biological Markers

Predictors of outcome among adult psychiatric first-admissions.